ovcar3

UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase (SETD8).

KIF18A-IN-2 is an inhibitor of mitotic kinesin Kif18A with IC50 of 28 nM and can be used in studies about chromosomal instability-associated vulnerabilities.

PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader targeting cyclin-dependent kinase 2 (CDK2). It inhibits the phosphorylation of the RB protein in the CDK2-dependent cell line OVCAR3, with an IC50 ranging from 100-500 nM.

WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.

PKMYT1-IN-8 (Compound 137) is an inhibitor of PKMYT1, with an IC50 value of 9 nM. It also inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2, exhibiting IC50 values of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. Additionally, PKMYT1-IN-8 suppresses the proliferation of cancer cells OVCAR3 with a GI50 of 2.02 μM.

KIF18A-IN-11 (Compound 13) is an effective inhibitor of KIF18A, exhibiting IC50 values below 100 nM in OVCAR3 and MDA-MB-157 cells. It is applicable for cancer research.

QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/D3, and 45 nM for CDK4/D1. It exhibits potent antitumor activity in the OVCAR3 ovarian cancer xenograft model, indicating its potential for use in cancer research [1].

CDK2-IN-19 (Compound 32) is a selective, orally active CDK2 inhibitor (K i: 0.18 nM) that demonstrates anticancer activity in mice with OVCAR3 tumors [1].

Menominin A is a cyclic peptide discovered in the freshwater sponge-associated cyanobacterium Nostoc sp., exhibiting cytotoxic properties. It shows anti-proliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 value of 3.1 μM. Menominin A holds potential for research in the field of cancer therapy.

Menominin B is a cyclic peptide identified in freshwater sponge-associated cyanobacteria Nostoc sp., known for its cytotoxic properties. It exhibits antiproliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 of 2.4 μM. Menominin B holds potential for research in the field of anticancer therapies.